Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
Public ClinicalTrials.gov record NCT06011798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular Edema
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema. The main questions the study aims to answer are: * Assess the efficacy of foselutoclax compared to aflibercept * Assess the safety and tolerability of foselutoclax
Study identification
- NCT ID
- NCT06011798
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2023
- Primary completion
- Jan 20, 2025
- Completion
- Apr 7, 2025
- Last update posted
- Aug 4, 2025
2023 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Retina Consultants | Bakersfield | California | 93309 | — |
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | — |
| Salehi Retina Institute Inc. | Huntington Beach | California | 92647 | — |
| Bay Area Retina Associates | Walnut Creek | California | 94598 | — |
| Advanced Vision Research Institute | Longmont | Colorado | 80503 | — |
| Rand Eye Institute | Deerfield Beach | Florida | 33064 | — |
| Florida Eye Associates | Melbourne | Florida | 32901 | — |
| Retina Vitreous Associates of Florida | St. Petersburg | Florida | 33711 | — |
| University Retina and Macula Associates | Lemont | Illinois | 60439 | — |
| Midwest Eye | Carmel | Indiana | 46290 | — |
| Cumberland Valley Retina Consultants | Hagerstown | Maryland | 21740 | — |
| Sierra Eye Associates | Reno | Nevada | 89502 | — |
| EyeHealth Northwest | Portland | Oregon | 97225 | — |
| Erie Retina Research, LLC | Erie | Pennsylvania | 16507 | — |
| Vision Research Solutions, PLLC | Philadelphia | Pennsylvania | 19141 | — |
| Retina Consultants of Carolina | Greenville | South Carolina | 29605 | — |
| Retina Research Institution of Texas | Abilene | Texas | 79606 | — |
| Austin Retina Associates | Round Rock | Texas | 78681 | — |
| Retina Center of Texas | Southlake | Texas | 76092 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06011798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2025 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06011798 live on ClinicalTrials.gov.